Werewolf Therapeutics, Inc.
General ticker "HOWL" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $60.2M (TTM average)
Werewolf Therapeutics, Inc. follows the US Stock Market performance with the rate: 42.8%.
Estimated limits based on current volatility of 5.7%: low 0.88$, high 0.99$
Factors to consider:
- Total employees count: 46 (-2.1%) as of 2024
- Top business risk factors: Economic downturns and volatility, Regulatory and compliance, Reimbursement and pricing pressures, Litigation risks, Operational and conduct risks
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.84$, 2.46$]
- 2025-12-31 to 2026-12-31 estimated range: [0.75$, 2.14$]
Financial Metrics affecting the HOWL estimates:
- Positive: with PPE of -0.9 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -84.26 <= 0.33
- Positive: 41.86 < Shareholder equity ratio, % of 57.82 <= 63.39
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term HOWL quotes
Long-term HOWL plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $16.40MM | $19.94MM | $1.89MM |
| Operating Expenses | $72.46MM | $60.45MM | $75.48MM |
| Operating Income | $-56.06MM | $-40.50MM | $-73.59MM |
| Non-Operating Income | $2.25MM | $3.13MM | $3.08MM |
| Interest Expense | $0.00MM | $3.14MM | $4.66MM |
| R&D Expense | $53.76MM | $41.78MM | $56.43MM |
| Income(Loss) | $-53.81MM | $-37.37MM | $-70.52MM |
| Profit(Loss)* | $-53.81MM | $-37.37MM | $-70.52MM |
| Stockholders Equity | $122.34MM | $111.37MM | $73.39MM |
| Assets | $160.25MM | $174.83MM | $126.93MM |
| Operating Cash Flow | $-40.60MM | $-32.61MM | $-56.19MM |
| Capital expenditure | $3.61MM | $0.77MM | $0.25MM |
| Investing Cash Flow | $-3.61MM | $-0.77MM | $-0.25MM |
| Financing Cash Flow | $15.91MM | $58.43MM | $13.08MM |
| Earnings Per Share** | $-1.86 | $-1.05 | $-1.63 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.